Table 3 The AGREE II Instrument
From: Systematic review of guideline-recommended medications prescribed for treatment of low back pain
AGREE II domains and items | Â |
|---|---|
Domain 1. Scope and Purpose | Â |
1. The overall objective(s) of the guideline is (are) specifically described | Â |
2. The health question(s) covered by the guideline is (are) specifically described | Â |
3. The population (patients, public, etc.) to whom the guideline is meant to apply is specifically described | Â |
Domain 2. Stakeholder Involvement | Â |
4. The guideline development group includes individuals from all relevant professional groups | Â |
5. The views and preferences of the target population (patients, public, etc.) have been sought | Â |
6. The target users of the guideline are clearly defined | Â |
Domain 3. Rigor of Development | Â |
7. Systematic methods were used to search for evidence | Â |
8. The criteria for selecting the evidence are clearly described | Â |
9. The strengths and limitations of the body of evidence are clearly described | Â |
10. The methods for formulating the recommendations are clearly described | Â |
11. The health benefits, side effects, and risks have been considered in formulating the recommendations | Â |
12. There is an explicit link between the recommendations and the supporting evidence | Â |
13. The guideline has been externally reviewed by experts prior to its publication | Â |
14. A procedure for updating the guideline is provided | Â |
Domain 4. Clarity of Presentation | Â |
15. The recommendations are specific and unambiguous | Â |
16. The different options for management of the condition or health issue are clearly presented | Â |
17. Key recommendations are easily identifiable | Â |
Domain 5. Applicability | Â |
18. The guideline describes facilitators and barriers to its application | Â |
19. The guideline provides advice and/or tools on how the recommendations can be put into practice | Â |
20. The potential resource implications of applying the recommendations have been considered | Â |
21. The guideline presents monitoring and/or auditing criteria | Â |
Domain 6. Ethical Independence | Â |
22. The views of the funding body have not influenced the content of the guideline | Â |
23. Competing interests of guideline development group members have been recorded and addressed | Â |